AGE RELATED MACULAR DEGENERATION.
- Resource Type
- Article
- Authors
- Jackson, Timothy L.; Kirkpatrick, Lucy
- Source
- BMJ: British Medical Journal (Overseas & Retired Doctors Edition). 9/3/2011, Vol. 343 Issue 7821, p437-437. 3/5p. 1 Graph.
- Subject
- *RETINAL degeneration
DRUGS & economics
- Language
- ISSN
- 1759-2151
The article discusses an economic evaluation that compared the costs of bevacizumab and ranibizumab, drugs for treating wet age related macular degeneration (AMD), in Great Britain. The study estimates that switching to bevacizumab would save the country 556 million pounds over three years. It notes that there seems an economic argument for renegotiating the price of ranibizumab and adopting bevacizumab in treating naive patients.